Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2025-03-19 Report Publication Anno…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024
Report Publication Announcement Classification · 98% confidence The document is titled "Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024" (Inventiva announces the date of publication and presentation of its 2024 financial results). It explicitly states when the 2024 financial results will be published (March 26, 2025) and when the conference call/webcast will occur (March 30, 2025). This document is not the financial report itself (like an ER or IR), but rather an announcement about the upcoming release and presentation of those results. According to Rule #2, a short document announcing the publication of a report falls under Report Publication Announcement (RPA).
2025-03-19 French
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Report Publication Announcement Classification · 98% confidence The document explicitly announces the schedule for the publication and presentation of the company's 2024 Full-Year Financial Results. It details the date the results will be published (March 26, 2025) and the date a conference call/webcast will be held to discuss these results (March 27, 2025). This structure—announcing the release of a report and scheduling a call to discuss it—is characteristic of a Report Publication Announcement (RPA). The document itself is not the full financial results (like a 10-K or IR) but an announcement about them. Given the short length (3250 chars) and the focus on scheduling the release and a conference call, RPA is the most appropriate classification, as per Rule 2.
2025-03-19 English
Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva announcing the publication of preclinical study results regarding their drug candidate, lanifibranor, in the scientific journal 'Biomedicine & Pharmacotherapy'. It details scientific findings, includes quotes from a professor, provides publication details (DOI, PMID), and includes standard company information and forward-looking statements typical of corporate news releases regarding research progress. This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about scientific progress and publication, which fits best under the general category of Investor Relations or a specific scientific update. Since there is no specific code for 'Scientific Publication Announcement' or 'Research Update', and the document is a formal announcement intended for investors and the public about company progress, it is classified as a general Regulatory Filing (RNS) as a broad category for non-standard, material announcements, or potentially an Investor Presentation (IP) if it were a slide deck, but here it is a news release. Given the nature of announcing scientific data publication, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it is highly specific scientific news. It is not an ER, IR, or IP. It is a press release announcing a publication, making RNS the best fit among the provided options for a general, material announcement.
2025-02-26 French
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Regulatory Filings Classification · 99% confidence The document is titled with an announcement: "Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study...". It details scientific findings, includes quotes from researchers, provides publication details (journal name, DOI, authors), and concludes with standard 'About the Company' and 'Contacts' sections typical of a press release. The content is an announcement about scientific data being published, not the full regulatory report itself (like 10-K or IR). Since it is a press release announcing scientific/research findings, it does not fit neatly into the specific categories like ER (Earnings Release) or MDA (Management Discussion). Given the nature of the announcement—a formal communication to the market about a specific event (publication of results)—it best fits the general regulatory announcement category, which is 'Regulatory Filings' (RNS), as it is a broad communication that doesn't match the more specific types like DIV, CAP, or ER. It is not a Report Publication Announcement (RPA) because it contains the substance of the findings, not just a notice that a report is available.
2025-02-26 English
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva announcing the initiation of a Phase 1 clinical trial for their drug 'lanifibranor' in Japan, in partnership with Hepalys Pharma. It contains standard corporate press release elements such as company background, project details, and forward-looking statements. Since it is an announcement of a specific corporate development (clinical trial milestone) rather than a full financial report, audit, or regulatory filing, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-02-20 French
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Regulatory Filings Classification · 95% confidence The document is a press release issued by Inventiva announcing the initiation of a Phase 1 clinical trial for their drug candidate, lanifibranor, in Japan in partnership with Hepalys Pharma. It provides details on the trial, the partnership, and forward-looking statements regarding clinical development. It does not constitute a formal financial report (like a 10-K or IR), nor is it a regulatory filing of a specific form type. In the context of financial document classification, press releases regarding clinical trial milestones are typically categorized as Regulatory Filings (RNS) when they do not fit into more specific categories like M&A or Earnings Releases.
2025-02-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.